Company profile for Henlius

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We are a leading biopharmaceutical company in China focusing on oncology and autoimmune diseases with the vision to offer high-quality, affordable and innovative biologics for patients worldwide. Founded in 2010 and headquartered in Shanghai, we have built an integrated and efficient global R&D platform with key facilities in Shanghai, Taipei and California collaborating with each other to ensure the highly productive and cost...
We are a leading biopharmaceutical company in China focusing on oncology and autoimmune diseases with the vision to offer high-quality, affordable and innovative biologics for patients worldwide. Founded in 2010 and headquartered in Shanghai, we have built an integrated and efficient global R&D platform with key facilities in Shanghai, Taipei and California collaborating with each other to ensure the highly productive and cost-efficient R&D processes. We established the first manufacturing facility featuring the core technology of single-use bioreactors in Shanghai Caohejing Hi-Technology Park in 2016.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
China
Address
Address
9/F, Innov Tower, Zone A, No. 1801 Hongmei Road, Xuhui District, Shanghai
Telephone
Telephone
021-33395800
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251117955804/en/Henlius-and-Organon-Announce-US-FDA-Approval-of-POHERDY-pertuzumab-dpzb-the-First-PERJETA-pertuzumab-Biosimilar-in-the-US

BUSINESSWIRE
17 Nov 2025

https://www.fiercepharma.com/pharma/organon-and-henlius-poherdy-first-biosimilar-roches-perjeta-approved-fda

FIERCE PHARMA
14 Nov 2025

https://www.pharmiweb.com/press-release/2025-09-19/european-commission-ec-approves-henlius-and-organon-s-bildyos-denosumab-and-bilprevda-denosum

PHARMAWEB
19 Sep 2025

https://www.prnewswire.com/news-releases/henlius-keeps-steady-growth-in-h1-2025-overseas-product-profits-soar-200-innovation-fuels-global-reach-302537677.html

PR NEWSWIRE
25 Aug 2025

https://www.prnewswire.com/news-releases/henlius-2025-global-rd-day-harnessing-the-power-of-innovation-to-propel-global-strategy-to-new-heights-302430536.html

PR NEWSWIRE
16 Apr 2025

https://www.prnewswire.com/news-releases/putting-patients-first-co-creating-a-bright-future-for-human-health-henlius-releases-2024-esg-report-302430528.html

PR NEWSWIRE
16 Apr 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

Inspections and registrations

Upload your audits for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty